

## *Curriculum Vitae*

**Martin Lukas Sos** Professor, Dr. med.  
d.o.b. June 26th, 1979, in Chelmza, Poland

### **University Education**

2015 professorial appointment  
2007 Doctorate Medicine, University of Cologne, Germany  
2000-2007 Studies of Medicine, University of Cologne, Germany

### **Scientific Career**

Since 2024 Member and project leader of the research training group GRK2338 "Targets in toxicology"  
Since 2024 Member of the DKTK München steering group  
Since 2023 Professor and Chair of Translational Oncology (W3), DKFZ/DKTK at the LMU in Munich  
Since 2022 Associate Editor, NPJ Precision Oncology  
Since 2019 Member of the Inclusivity, Diversity and Gender Committee of the CRC1399  
Since 2019 Co-founder and shareholder of PearlRiver Bio GmbH (now Centessa Pharmaceuticals)  
2015-2023 Professor for Molecular Pathology (W2), University of Cologne  
2014-2015 Junior Group Leader, Department of Translational Genomics, University of Cologne, Germany  
2012-2014 Postdoctoral Fellow, Howard Hughes Medical Institute, Cellular and Molecular Pharmacology, UCSF, San Francisco, USA  
2010-2012 Clinical Research Fellow at the Center of Integrated Oncology, Lung Cancer Group Cologne, University of Cologne, Germany  
2007-2010 Postdoctoral Fellow, Max-Planck Institute for Neurological Research, Cologne, Germany  
2007 MD (summa cum laude), Medical Faculty, University of Cologne, Germany

### **Awards and Honors**

2016 Chair of Session and Member of Poster Award Committee, Klenk Symposium 2016, Cologne, Germany  
2012-2014 Young Investigator Award, Prostate Cancer Foundation (PCF) USA  
2013 Scholar-in-Training Award, AACR - Aflac  
2011 - 2013 Young Investigator Award, Intern. Association for the Study of Lung Cancer (IASLC)  
2010 - 2011 Scholar-in-Training Award, AACR - Pezcoller Foundation  
2009 Scholar-in-Training Award, American Association for Cancer Research (AACR) 2008 Award for outstanding medical thesis, German Association of Hematology and Oncology (DGHO)

### **Citation Record**

*Total citations: 18602; h-index:45; h-index since 2021: 33* (Google Scholar March 11<sup>th</sup>, 2026)

### Top-10 selected Publications

1. Sanchez-Cespedes M, Lockwood WW, Suda K, Gardner EE, Mitsudomi T, Politi K, Rolfo C, Sen T, **Sos ML**, Tammela T, Wynes MW, Tsao MS, Berger AH. Tolerance and resistance to targeted therapy in non-small cell lung cancer: Emerging concepts and strategies. *JTO Clinical and Research Reports* (2025). DOI: [10.1016/j.jtocrr.2025.100944](https://doi.org/10.1016/j.jtocrr.2025.100944)
2. Sakthivelu V, Schmitt A, Odenthal F, [...], **Sos ML**, Reifenberger G, Fischer M, Adriaensen D, Büttner R, Sage J, Brouns I, Rad R, Thomas RK, Anstötz M, Rizzoli SO, Bergami M, Motori E, Reinhardt HC, Beleggia F. Functional synapses between neurons and small cell lung cancer. *Nature*. (2025). DOI: [10.1038/s41586-025-09434-9](https://doi.org/10.1038/s41586-025-09434-9)
3. Valdez Capuccino L, Kleitke T, Szokol B, Svajda L, Martin F, Bonechi F, Krekó M, Azami S, Montinaro A, Wang Y, Nikolov V, Kaiser L, Bonasera D, Saggau J, Scholz T, Schmitt A, Beleggia F, Reinhardt HC, George J, Liccardi G, Walczak H, Tóvári J, Brägelmann J, Montero J, **Sos ML**, Órfi L, Peltzer N. CDK9 inhibition as an effective therapy for small cell lung cancer. *Cell Death Dis*. (2024) 15(5):345. DOI: [10.1038/s41419-024-06724-4](https://doi.org/10.1038/s41419-024-06724-4)
4. Müller N, Lorenz C, Ostendorp J, Heisel FS, Friese UP, Cartolano M, Plenker D, Tumbrink H, Heimsoeth A, Baedeker P, Weiss J, Ortiz-Cuaran S, Büttner R, Peifer M, Thomas RK, **Sos ML**, Berg J, Brägelmann J. Characterizing evolutionary dynamics reveals strategies to exhaust the spectrum of subclonal resistance in EGFR-mutant lung cancer. *Cancer Res* (2023) 83(15):2471-2479. DOI: [10.1158/0008-5472.CAN-22-2605](https://doi.org/10.1158/0008-5472.CAN-22-2605)
5. Brägelmann J, Lorenz C, Borchmann S, [...], **Sos ML**. MAPK-mediated inflammatory reprogramming sensitizes tumors to targeted activation of innate immunity sensor RIG-I. *Nat Commun* (2021) 12(1):5505. DOI: [10.1038/s41467-021-25728-8](https://doi.org/10.1038/s41467-021-25728-8)
6. Dammert MA, Brägelmann J, Olsen RR, Böhm S, Monhasery N, Whitney CP, Chalishazar MD, Tumbrink HL, Guthrie MR, Klein S, Ireland AS, Ryan J, Schmitt A, Marx A, Ozretić L, Castiglione R, Lorenz C, Jachimowicz RD, Wolf E, Thomas RK, Poirier JT, Büttner R, Sen T, Byers LA, Reinhardt HC, Letai A, Oliver TG, **Sos ML**. MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. *Nat Commun*. 2019; 10(1):3485. DOI: [10.1038/s41467-019-11371-x](https://doi.org/10.1038/s41467-019-11371-x)
7. Fassunke J, Müller F, [...], **Sos ML**. Overcoming EGFR(G724S)-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. *Nat Commun*. 2018; 9(1):4655. DOI: [10.1038/s41467-018-07078-0](https://doi.org/10.1038/s41467-018-07078-0)
8. Brägelmann J, Dammert MA, [...], **Sos ML**. Systematic kinase inhibitor profiling identifies CDK9 as a synthetic lethal target in NUT midline carcinoma. *Cell Reports*. 2017; 20(12):2833-2845. DOI: [10.1016/j.celrep.2017.08.082](https://doi.org/10.1016/j.celrep.2017.08.082)
9. Plenker D, Riedel M, [...], **Sos ML**. Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. *Sci Transl Med*. 2017; 14; 9(394). DOI: [0.1126/scitranslmed.aah6144](https://doi.org/10.1126/scitranslmed.aah6144)
10. Mollaoglu G, Guthrie MR, [...], **Sos ML**, Oliver TG. MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to Aurora kinase inhibition. *Cancer Cell* 2017; 31:1-16. DOI: [10.1016/j.ccell.2016.12.005](https://doi.org/10.1016/j.ccell.2016.12.005)